Mitchell J. Frederick

Baylor College of Medicine — United States

Medicine · Health Sciences

42h-index11.3kcitations480works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(114), RNA modifications and cancer(72), Cancer Genomics and Diagnostics(63), Head and Neck Cancer Studies(60), Epigenetics and DNA Methylation(58)

Publications479 total

Establishment and characterization of a new immortalized human oral keratinocyte (HOK) cell line harboring various TP53 mutations
Oral Oncology·2025
Supplementary Figure S9 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S3 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S6 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Materials and Methods S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S2 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S7 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S8 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S4 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S2 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S4 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S3 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figures from Sustained Aurora Kinase B Expression Confers Resistance to PI3K Inhibition in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary tables from Sustained Aurora Kinase B Expression Confers Resistance to PI3K Inhibition in Head and Neck Squamous Cell Carcinoma
2025Open Access
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting
British Journal of Cancer·2025Open Access
Supplementary figure 7 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
2025Open Access
page 1 of 24Next →

Frequent Co-authors

Jeffrey N. Myers(25), Curtis R. Pickering(22), Adel K. El‐Naggar(14), Gary L. Clayman(14), Jing Wang(10), Ying C. Henderson(10), Mei Zhao(8), Abdullah A. Osman(8), Heath D. Skinner(8), Faye M. Johnson(8), Li Shen(7), David A. Wheeler(6), David M. Neskey(6), Ameeta A. Patel(6), Vlad C. Sandulache(6), Jennifer Drummond(5), Arumugam Jayakumar(5), Xiayu Rao(5), Nene N. Kalu(5), Jiexin Zhang(4)